In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (5/05)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, New Approaches to Heart Valve Repair and Replacement, features profiles of 3F Therapeutics, Arbor Surgical Technologies and Heart Leaflet Technologies. Plus these Start-Ups Across Health Care: Neotropix, NeuroHealing Pharmaceuticals, Othera Pharmaceuticals and Vitra Bioscience.

You may also be interested in...



The MPP And Merck Partner For Molnupiravir In Lower-Income Countries

The Medicines Patent Pool has signed its first agreement to provide access for a COVID-19 medical technology with Merck & Co, to increase access of generic molnupiravir to 150 lower income countries. 

Industry Leaders Call For Legal Certainty On Northern Ireland Regulation

The European Commission’s proposals for solving the post-Brexit regulatory problems relating to the Northern Ireland market are welcome but they do not go far enough and risk leaving suppliers in a legal limbo, says the off-patent medicines industry.

NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive

SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.

Related Companies

UsernamePublicRestriction

Register

IV002573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel